Show simple item record

dc.contributor.authorReid, Monica L.
dc.contributor.authorBrown, Marc
dc.contributor.authorJones, Stuart A.
dc.date.accessioned2012-12-17T14:29:40Z
dc.date.available2012-12-17T14:29:40Z
dc.date.issued2008-11
dc.identifier.citationReid , M L , Brown , M & Jones , S A 2008 , ' Manipulation of corticosteroid release from a transiently supersaturated topical metered dose aerosol using a residual miscible co-solvent ' , Pharmaceutical Research , vol. 25 , no. 11 , pp. 2573-2580 . https://doi.org/10.1007/s11095-008-9675-3
dc.identifier.issn0724-8741
dc.identifier.otherPURE: 627494
dc.identifier.otherPURE UUID: 7bf41b57-016d-4f73-ba7c-5462545f0a10
dc.identifier.otherWOS: 000259742300012
dc.identifier.otherScopus: 53849104256
dc.identifier.urihttp://hdl.handle.net/2299/9421
dc.description.abstractPurpose. The creation of supersaturation transiently after application overcomes the issue of drug instability. However, if the solvents used to drive supersaturation evaporate too quickly, drug recrystallisation or rapid film drying can occur which will inhibit drug release. As such the effects of a residual solvent, poly(ethylene glycol) 400 (PEG), on the release, mobility and supersaturation kinetics of a transiently supersaturated formulation were studied. Materials and Methods. Metered dose aerosol (MDA) formulations consisting of hydrofluoroalkane 134a, ethanol, poly(vinyl pyrrolidone) K90, beclomethasone dipropionate (BDP), and 0%, 5% or 10% w/w PEG were prepared in canisters sealed with metered dose valves and tested for release and adhesion over time. Results. The addition of 10% PEG to the MDA formulation resulted in a significant reduction (p < 0.05) in steady state drug release rate (230.4 +/- 17.3 mu g/cm(2)/h for 0% PEG MDA, 83.6 +/- 4.9 mu g/cm(2)/h for 10% PEG MDA). The presence of PEG caused a delay in dose depletion (2 h for 0% PEG MDA versus 4 h for 10% PEG), retarded supersaturation kinetics and increased film drying time. Conclusion. Whilst equivalent amounts of BDP were released, the residual solvent altered the drug release profile to achieve more constant delivery.en
dc.format.extent8
dc.language.isoeng
dc.relation.ispartofPharmaceutical Research
dc.subjectaerosol
dc.subjectbeclomethasone dipropionate
dc.subjectcorticosteroids
dc.subjectdiffusion
dc.subjectin vitro models
dc.subjectpercutaneous drug delivery
dc.subjectsolubility
dc.subjectsupersaturation
dc.subjectDRUG-DELIVERY SYSTEMS
dc.subjectPOLY(N-VINYL PYRROLIDONE)
dc.subjectPOLY(ETHYLENE GLYCOL)
dc.subjectMOLECULAR-WEIGHT
dc.subjectPROBE TACK
dc.subjectIN-VITRO
dc.subjectSKIN
dc.subjectBLENDS
dc.subjectTEMPERATURE
dc.subjectFORMULATION
dc.titleManipulation of corticosteroid release from a transiently supersaturated topical metered dose aerosol using a residual miscible co-solventen
dc.contributor.institutionHealth & Human Sciences Research Institute
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionDepartment of Pharmacy
dc.contributor.institutionCentre for Research into Topical Drug Delivery and Toxicology
dc.contributor.institutionPharmaceutics
dc.contributor.institutionSkin and Nail Group
dc.contributor.institutionAirway Group
dc.contributor.institutionBioadhesive Drug Delivery Group
dc.contributor.institutionNanopharmaceutics
dc.contributor.institutionPharmaceutical Analysis and Product Characterisation
dc.description.statusPeer reviewed
rioxxterms.versionVoR
rioxxterms.versionofrecordhttps://doi.org/10.1007/s11095-008-9675-3
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record